ERBB2 and central nervous system neoplasm: Finally, multiple trials are evaluating CAR-T cell immunotherapy targeting B7-H3-expressing pontine DMG (NCT04185038) or solid tumors (NCT04897321), HER-2 in recurrent or refractory HER2-positive CNS tumors (NCT03500991, NCT02442297), IL13Rα2 in recurrent or refractory malignant gliomas (NCT02208362), EGFR in pediatric recurrent or refractory EGFR positive CNS tumors (NCT03638167), and GD2-expressing CNS tumors including DMG (NCT04196413, NCT04099797) (Tables 2–4).